1. Inhibition of PD-L1-mediated tumor-promoting signaling is involved in the anti-cancer activity of β-tocotrienol.
- Author
-
Sun, Zhenou, Yin, Shutao, Zhao, Chong, Fan, Lihong, and Hu, Hongbo
- Subjects
- *
PROGRAMMED cell death 1 receptors , *PROGRAMMED death-ligand 1 , *ANTINEOPLASTIC agents , *IMMUNE checkpoint proteins , *JAK-STAT pathway , *VITAMIN E - Abstract
Programmed death-ligand 1 (PD-L1), a critical immune checkpoint ligand, is commonly overexpressed on the surface of many tumor types including lung and prostate cancer. PD-L1 can exert cancer-promoting activity through either suppressing T cell-mediated immune response or activating tumor-intrinsic signaling. Here, we demonstrated that β-tocotrienol (β-T3), an isomer of vitamin E, effectively inhibited PD-L1 expression both in vitro and in vivo , which was mechanistically associated inactivating JAK2/STAT3 pathway. Down-regulating PD-L1 expression by β-T3 led to enhanced immune response and inactivation of PD-L1-induced tumor-intrinsic signaling, which in turn contributed to its anticancer activity. This study uncovered a novel mechanism involved in the anticancer effect of β-T3. • ∗β-tocotrienol inhibits PD-L1 expression both in vitro and in vivo. • ∗β-tocotrienol mitigates PD-L1-mediated immune suppression. • ∗β-tocotrienol suppresses PD-L1-meidtated tumor-intrinsic signaling. • ∗β-tocotrienol inhibits tumor growth in vivo associated with enhanced immune response. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF